Final overall survival from a phase 3 trial of <i>nab</i>-paclitaxel versus dacarbazine (DTIC) in chemotherapy-naive patients with metastatic melanoma.
Evan M. Hersh, Axel Hauschild(University Hospital Schleswig-Holstein), Michael P. Brown(South Australia Pathology), Alessandro Testori(European Organisation for Research and Treatment of Cancer), Shailender Bhatia(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Richard Kefford(Broad Institute), Markus F. Renschler(Princess Margaret Cancer Centre), Carmen Loquai(Johannes Gutenberg University Mainz), Andrew Haydon(The Alfred Hospital), Mingyu Li, Caroline Robert(Institut Gustave Roussy), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Ileana Elias, Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum)
Cited by 5
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k